GLP-1 weight loss claims on TikTok: what Canada creators get right and wrong

What's this video probably claiming?

Canadian GLP-1 content on TikTok follows a fairly predictable script. Accounts like this one typically document personal weight loss journeys on semaglutide or tirzepatide, often purchased through Canadian compounding pharmacies or telehealth platforms operating under Health Canada's Special Access Program. The claims usually cluster around dramatic before-and-after results, specific numbers like "I lost 30 pounds in 3 months," commentary on dosing schedules, and sometimes comparisons between brand-name Ozempic (available in Canada for diabetes) and compounded alternatives. There's also a growing sub-genre of Canadian GLP-1 TikTok that talks about drug shortages, cost barriers, and how to navigate the system. Without a transcript, we're working from context, but the creator handle alone tells us enough. This is almost certainly someone sharing their personal experience, possibly with implicit or explicit claims about what dosing worked for them, and that's where things get clinically complicated.

What does the science actually show?

The clinical data on semaglutide for weight management is genuinely strong. The STEP 1 trial (Wilding et al., 2021, NEJM) showed that 2.4mg weekly subcutaneous semaglutide produced an average body weight reduction of 14.9% over 68 weeks in adults with obesity. Tirzepatide data is even more striking: the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed up to 22.5% mean weight loss at the highest 15mg dose. These are not trivial effects. They are also highly dose-dependent, and the titration schedules used in trials are specific and slow for a reason. Side effect rates, primarily nausea, vomiting, and gastrointestinal symptoms, were significant. In STEP 1, 44.2% of semaglutide participants reported nausea. What personal TikTok accounts almost never convey is the statistical distribution: these are means. A meaningful portion of participants lose far less, and some lose almost nothing.

Where does the social media noise diverge from clinical reality?

The biggest gap between TikTok GLP-1 content and clinical reality is survivorship bias. The people posting about their results are, by definition, people who tolerated the medication and saw results worth posting about. You don't hear as much from the roughly 5-10% of trial participants who discontinued due to adverse events, or from those who lost only 4-5% of body weight. Canadian-specific content adds another wrinkle: Health Canada has not approved semaglutide 2.4mg (Wegovy) for weight management in Canada as of 2024, meaning many Canadians are accessing compounded semaglutide through pathways that operate in a regulatory grey zone. Compounded formulations are not bioequivalent to brand-name products under Health Canada or FDA standards, and that is not a technicality. It has real implications for dosing accuracy and sterility standards. Creators rarely address this distinction, and some actively conflate the two.

What should you actually know?

If you're in Canada considering a GLP-1 medication, here is what the evidence actually supports. First, these drugs work for many people at clinically meaningful effect sizes, but individual variation is large. Second, the titration schedule matters: rushing to a higher dose increases GI side effects without necessarily improving outcomes faster. Third, the weight loss is not permanent if the drug is stopped. The STEP 1 extension study (Wilding et al., 2022, Diabetes, Obesity and Metabolism) showed participants regained two-thirds of lost weight within a year of stopping semaglutide. Fourth, anyone presenting compounded semaglutide as identical to Ozempic or Wegovy is making a claim that regulatory bodies in both Canada and the United States explicitly reject. Fifth, GLP-1 medications for weight management require medical supervision, not because of bureaucratic gatekeeping, but because thyroid C-cell tumors were observed in rodent studies and pancreatitis risk requires monitoring. A TikTok account is not a substitute for that oversight.